We don’t answer to a holding company or have growth goals or profitability targets. Our team has one objective: deliver results and ensure client happiness.
Clients
 |
AblexisAblexis is creating the AlivaMab Mouse, an innovative, next-generation transgenic mouse platform intended to provide the foundation for the efficient discovery and development of the next wave of human therapeutic antibodies.
|
 |
AchaogenAchaogen is dedicated to addressing serious medical needs caused by the development of bacterial resistance to antibiotics.
|
 |
AcucelaAcucela is leveraging promising science in visual cycle modulation to develop new methods for treating blinding eye diseases that affect tens of millions of people worldwide.
|
 |
Agios PharmaceuticalsAgios Pharmaceuticals is a biopharmaceutical company dedicated to the development of novel therapeutics in the emerging field of cancer metabolism, which represents a breakthrough understanding of how cancer cells adapt to use more nutrients than normal cells to promote their survival and growth.
|
 |
Aileron TherapeuticsAileron Therapeutics is a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides, which are a breakthrough solution to address thousands of therapeutically important yet currently undruggable targets. Aileron is building a robust pipeline of therapeutics for the treatment of cancer, infectious disease, metabolic disease and immune/inflammatory diseases.
|
 |
Allena Pharmaceuticals, Inc.Allena Pharmaceuticals, Inc. is developing and commercializing non-systemic protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrologic and urologic conditions. The company’s proven approach enables the design and development of oral protein therapies that remain in the gastrointestinal (GI) tract, where the protein exerts its therapeutic effect by reducing toxic metabolites without being absorbed into the bloodstream. Led by a proven management team with deep expertise in protein therapeutic design and development, Allena is committed to bringing breakthrough new treatments to patients with unmet medical needs. Based in Newton, Mass., the company is backed by top-tier venture investors Bessemer Venture Partners, Frazier Healthcare and Third Rock Ventures.
|
 |
AVEO Pharmaceuticals, Inc.AVEO Pharmaceuticals (NASDAQ: AVEO) is a cancer therapeutics company committed to discovering, developing and commercializing targeted therapies to impact patients’ lives. The company’s lead product candidate, tivozanib, is currently being investigated in a global, randomized Phase 3 clinical trial called TIVO-1 comparing tivozanib to sorafenib in patients with advanced renal cell carcinoma, as well as additional clinical studies in other solid tumor types.
|
 |
bluebird biobluebird bio is developing a broadly applicable gene therapy platform for the creation of novel treatments for diseases with few or no clinical options. The company’s novel approach uses stem cells harvested from the patient’s bone marrow into which a healthy version of the disease causing gene is inserted. After being grown in culture, those cells are given back to the patient. bluebird bio’s approach represents a true paradigm shift in the treatment of severe genetic diseases by eliminating the potential complications associated with donor cell transplantation and presenting a one-time transformative therapy.
|
 |
BlueprintBlueprint Medicines is driving the development of personalized, highly-selective cancer therapies that harness the growing understanding of the molecular blueprint of cancer. Using its powerful Insights-to-Validation™ Platform and proprietary chemical library, Blueprint Medicines is working to develop new therapeutic compounds and combination therapies that target the molecular aberrations that cause cancer and the emerging resistance mechanisms that make it increasingly difficult to treat. Founded in 2011 by a proven team of scientists and entrepreneurs with world-renowned expertise in the development of targeted cancer therapies, cancer genomics, and rational drug development, Blueprint Medicines is poised to realize the promise of the cancer data “revolution”: truly personalized therapies that improve outcomes and shift cancer to a manageable condition. http://www.blueprintmedicines.com
|
 |
Catabasis Pharmaceuticals, Inc.Catabasis is leveraging the therapeutic potential of omega-3 fatty acids and other clinically validated compounds to create new medicines for the treatment of inflammatory and metabolic diseases. http://www.catabasispharma.com/
|
 |
Constellation PharmaceuticalsConstellation Pharmaceuticals is a leading biopharmaceutical company dedicated to the discovery and development of novel therapeutics in the emerging field of epigenetics, a growing field of science that focuses on chromatin modifiers and the regulation of gene expression. The Company's academic founders are thought leaders in epigenetics responsible for numerous seminal advances. Constellation Pharmaceuticals is located in Cambridge, Massachusetts. http://www.constellationpharma.com/
|
 |
CytomX TherapeuticsCytomX Therapeutics is an early stage biotechnology company developing Probodies™, or proteolytically-activated antibodies. Probodies, by their ability to site-direct the activity of antibodies, will result in an improved therapeutic index for validated targets as well as enable the drugging of targets with broad tissue expression. The company’s mission, alone and with the help of partners, is to provide patients with more effective and less toxic therapies for severe illnesses such as cancer and inflammatory diseases.
|
 |
Dicerna PharmaceuticalsDicerna Pharmaceuticals is a private, venture-backed biopharmaceutical company developing novel therapeutic agents in multiple therapeutic areas based on its proprietary Dicer Substrate Technology™, which triggers RNA interference (RNAi) in a potent and specific manner.
|
 |
Foundation MedicineFoundation Medicine is dedicated to the development of a comprehensive solution that enables physicians to personalize cancer treatment for their patients. By harnessing emerging technologies to develop unparalleled tests that identify and interpret an ever-growing set of actionable genomic and other molecular alterations, Foundation is truly enabling personalized cancer medicine.
|
 |
GI DynamicsGI Dynamics, Inc. (ASX: GID) is pioneering the development and commercialization of effective, non-surgical treatments targeting the large and growing global patient populations with type 2 diabetes and obesity. The company’s patented EndoBarrier™ Technology offers patients ‘one solution’ to improve and control their glucose levels and lose weight at the same time. The EndoBarrier has CE mark approval in Europe and TGA approval in Australia for up to 12 months of treatment, and is available in select markets in Europe and South America. GI Dynamics has also received an investigational device exemption approval to commence a pilot clinical trial of the EndoBarrier in the U.S.
|
 |
InfraReDx, Inc.InfraReDx, Inc. is a medical device company focused on developing diagnostic cardiovascular imaging systems. InfraReDx is the maker of the LipiScan™ coronary imaging system, the only FDA cleared product to detect and characterize lipid core plaque, a vulnerable plaque suspected to cause most heart attacks and complicate stenting procedures. The catheter-based LipiScan system is in use by interventional cardiologists to better inform treatment decisions and improve outcomes for their patients.
|
 |
Lantheus Medical Imaging, Inc.Lantheus Medical Imaging is a worldwide leader in medical imaging, with headquarters in North Billerica, Massachusetts, and nearly 700 employees worldwide with offices in Puerto Rico, Canada, and Australia.
|
 |
Lycera Corp.Lycera Corp. is focused on the discovery and development of small-molecule immunomodulators for the treatment of patients with autoimmune diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease.
|
 |
MitomicsMitomics is the leading developer of molecular tests based on the mitochondrial genome. Leveraging its unparalleled insights into the role of mitochondria in cancer, Mitomics has developed a proprietary, potentially paradigm shifting test to rule out prostate cancer in high risk men without the need for further invasive biopsy procedures.
|
 |
NinePoint Medical, Inc.NinePoint Medical, Inc. is a transformational medical device company developing innovative, real-time, in vivo pathology devices. http://www.ninepointmedical.com/
|
 |
OpGen, Inc.OpGen, Inc. is a leading innovator and developer of genomic solutions for the analysis of genetic variation and biological function. The company has developed a platform for its proprietary Optical Mapping Technology. The Argus™ Optical Mapping System and MapIt™ Services provide high resolution, whole genome restriction maps for strain typing, comparative genomics and sequence assembly of microbial genomes to the life sciences market.
|
 |
Pacira Pharmaceuticals, Inc.Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) is an emerging specialty pharmaceutical company focused on the development, commercialization and manufacture of novel pharmaceutical products, based on its proprietary DepoFoam drug delivery technology. In February 2011, the company successfully completed its initial public offering. The company's most advanced product candidate, EXPAREL™, has completed Phase 3 clinical development for postoperative analgesia by infiltration and has an upcoming PDUFA date in July 2011. EXPAREL is designed to address the limitations of widely used medications by enhancing their dosing and/or administration profile.
|
 |
PTC Therapeutics, Inc.PTC Therapeutics, Inc. (PTC) is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, proprietary small-molecule drugs that target post-transcriptional control processes.
|
 |
SAGE TherapeuticsSAGE Therapeutics is a central nervous system (CNS) product focused company building a portfolio of new therapies to meet the growing unmet need in a range of CNS disorders, including schizophrenia, depression, pain, and traumatic brain injury. SAGE Therapeutics' proprietary Positive and Negative Allosteric Modulator (PANAM) chemistry platform targets the primary excitatory and inhibitory neurotransmitter systems in the brain and enables the development of allosteric modulators that fine tune and balance neuronal activity that is disrupted in CNS disorders.
|
 |
Sunshine HeartSunshine Heart is a global medical device company committed to the commercialization of the C-Pulse Heart Assist System, an implantable, non-blood contacting, heart assist therapy for the treatment of moderate to severe heart failure which can be implanted using a minimally invasive procedure. C-Pulse is designed to relieve the symptoms of heart failure through the use of counter-pulsation technology which enables an increase in cardiac output, an increase in coronary blood flow and a reduction in the heart's pumping load. The Company has completed enrollment of an approved U.S. Food and Drug Administration (FDA) 20 patient feasibility clinical trial with the C-Pulse System. Sunshine Heart is a Delaware-based Corporation headquartered in Minneapolis with a subsidiary presence in Australia. The Company has been listed on the ASX since September 2004.
|
 |
TengionTengion is a leader in the field of regenerative medicine. We are developing new human organs and tissues that are derived from a patient's own cells.
|
 |
Third Rock VenturesThird Rock Ventures is a venture firm focused on life sciences, investing and launching companies that make a difference in people’s lives. Collaborating with entrepreneurs, the Third Rock team applies its deep expertise to establish the roadmap and building blocks for a rapidly growing and highly successful life sciences company. The Third Rock team has a unique vision and experience in building great companies, extensive academic and industry networks and a collective track record for creatively managing the value creation path to deliver exceptional performance.
|
 |
Titan Pharmaceuticals, Inc.Titan Pharmaceuticals, Inc. (TTNP.OB) is a biopharmaceutical company focused in the development of products for the treatment of central nervous system diseases. Titan's first out licensed product, Fanapt® (iloperidone) is an atypical antipsychotic approved in the U.S. in May 2009 for the treatment of schizophrenia in adult patients. Titan's second product, Probuphine, is nearing completion of the Phase 3 clinical development program in the treatment of opioid addiction.
|
 |
Variation BiotechnologiesVariation Biotechnologies is a vaccine development company dedicated to the innovative formulation, development and delivery of thermostable vaccines that expand and enhance vaccine protection in both established and emerging markets. VBI’s innovative approach to vaccine development and growing pipeline of vaccine programs address significant market opportunity and are designed to answer critical unmet medical need. http://www.variationbiotech.com
|
 |
VBL TherapeuticsVBL Therapeutics is an innovative, clinical stage biotechnology company committed to the development of novel treatments for immuno-inflammatory diseases and cancer.
|
 |
WarpDrive BioWarp Drive Bio is driving the reemergence of natural products in the era of genomics to create breakthrough treatments that make an important difference in the lives of patients. Built upon the belief that nature is the world’s most powerful medicinal chemist, Warp Drive Bio is deploying a battery of state-of-the-art technologies to access powerful drugs that are now hidden within microbes. Key to the Warp Drive Bio approach is the company’s proprietary “genomic search engine” and customized search queries that enable hidden natural products to be revealed on the basis of their distinctive genomic signature. Launched in 2011 through a groundbreaking strategic partnership with Sanofi and with financing from Third Rock Ventures and Greylock Partners, the company was founded by renowned scientist Dr. Gregory Verdine, along with Dr. George Church and Dr. James Wells.
|